TNXP — Tonix Pharmaceuticals Holding Corp.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1430306 ·
Last close
$9.90
Market Cap
$169.80M
52W High
$25.52
52W Low
$9.40
ADV30
458,274
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 13,544,000 | 12,841,000 | -41,935,000 | -40,552,000 | 254,088,000 | 176,232,000 | 31,807,000 |
| Mar 2026 | 6,878,000 | 5,300,000 | -41,537,000 | -40,194,000 | 257,912,000 | 185,470,000 | 30,775,000 |
| Dec 2025 | 5,390,000 | 4,332,000 | -48,215,000 | -46,910,000 | 277,171,000 | 207,637,000 | 32,021,000 |
| Sep 2025 | 3,290,000 | 1,923,000 | -32,085,000 | -32,010,000 | 252,440,000 | 190,055,000 | 21,297,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-125,583,000
Investing CF
$-6,214,000
Financing CF
$185,202,000
CapEx
$-6,111,000
Dividends Paid
—
Buybacks
$-10,713,000
EPS Diluted TTM
$-14.36
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-894,909,000
Inventory
$4,645,000
Receivables
$12,677,000
ST Investments
—
EBIT TTM
$-147,717,000
Pretax Income TTM
$-147,386,000
Interest Exp TTM
$0
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$29,102,000
EBITDA
$-163,302,000
Free Cash Flow
$-95,760,248
Enterprise Value
$28,622,654
Total Cash
$176,232,000
Total Debt
$1,272,000
Shares Out
17,151,024
Trailing EPS
$-13.09
Book Value
$13.24
ROE
-81.8%
ROA
-46.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 13,107,000 | -122,691,000 | -124,021,000 | 277,171,000 | 32,021,000 | 245,150,000 | -99,844,000 |
| Dec 2024 | 10,094,000 | -75,150,000 | -130,036,000 | 162,890,000 | 23,332,000 | 139,558,000 | -60,925,000 |
| Dec 2023 | 7,768,000 | -118,380,000 | -116,658,000 | 154,457,000 | 48,932,000 | 105,525,000 | -102,003,000 |
| Dec 2022 | 0 | -112,091,000 | -110,218,000 | 225,690,000 | 18,508,000 | 207,182,000 | -98,053,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-7.88
Max Pain — expiry 2027-03-19 (volume-derived — Yahoo OI feed degraded)
max pain strike: $10.00 · spot: $9.90 · call volume: 105 · put volume: 7
Expected Move to 2027-03-19:
±$5.99
(60.51%) —
implied range
$3.91 –
$15.89
· ATM straddle on $10.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ORGO | Organogenesis Holdings Inc. | $177.57M | $1.38 | — |
| NERV | Minerva Neurosciences, Inc. | $162.34M | $3.40 | — |
| PEPG | PepGen Inc. | $179.15M | $2.59 | — |
| ADCT | ADC Therapeutics SA | $160.86M | $1.26 | — |
| NBP | NovaBridge Biosciences | $157.28M | $1.36 | — |
News headlines (Yahoo Finance, 1h cache)
Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears
2026-09-12 02:01 · Yahoo
Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer
2026-09-08 11:00 · Yahoo
TNXP: $11.0 Million in Tonmya® Net Revenue in 2Q26
2026-09-02 13:38 · Yahoo
Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference
2026-09-02 11:00 · Yahoo
Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline
2026-08-18 07:01 · Yahoo
Tonix Pharmaceuticals (TNXP) Q2 2026 Earnings Call Transcript
2026-08-17 14:44 · Yahoo
Tonix Pharmaceuticals Holding Corp (TNXP) (Q2 2026) Earnings Call Highlights: TONMYA Surges ...
2026-08-10 21:01 · Yahoo
Tonix Pharmaceuticals Q2 Earnings Call Highlights
2026-08-10 16:04 · Yahoo
Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S
2026-08-03 11:00 · Yahoo
Tonix Expands TONMYA Medicare Coverage with New Payer Agreement (TNXP)
2026-07-13 12:21 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.